Super‐Enhancer Reprograming Driven by SOX9 and TCF7L2 Represents Transcription‐Targeted Therapeutic Vulnerability for Treating Gallbladder Cancer
2024

Targeting Gallbladder Cancer with SOX9 and TCF7L2

Sample size: 10 publication 10 minutes Evidence: high

Author Information

Author(s): Yan Siyuan, Liu Zhaonan, Wang Teng, Sui Yi, Wu Xiangsong, Shen Jiayi, Pu Peng, Yang Yang, Wu Sizhong, Qiu Shimei, Wang Ziyi, Jiang Xiaoqing, Feng Feiling, Li Guoqiang, Liu FaTao, Zhao Chaoxian, Liu Ke, Feng Jiayi, Li Maolan, Man Kwan, Wang Chaochen, Tang Yujie, Liu Yingbin

Primary Institution: Shanghai Jiao Tong University School of Medicine

Hypothesis

SOX9 and TCF7L2 form a core regulatory circuitry that drives super-enhancer reprogramming in gallbladder cancer.

Conclusion

The study reveals that gallbladder cancer cells with high levels of SOX9 and TCF7L2 are more susceptible to CDK7 inhibition therapy.

Supporting Evidence

  • SOX9 and TCF7L2 co-occupy each other's super-enhancer regions.
  • Patients with high levels of SOX9 and TCF7L2 have worse prognosis.
  • SOX9/TCF7L2 double-high gallbladder cancer models are sensitive to CDK7 inhibition therapy.

Takeaway

This study found that two proteins, SOX9 and TCF7L2, work together in gallbladder cancer cells, making them easier to treat with a specific type of medicine.

Methodology

The genomic distribution of H3K27ac was profiled in gallbladder cancer tissue and cell line samples to establish the super-enhancer landscape.

Participant Demographics

The study included 8 primary gallbladder cancer samples and 2 benign gallbladder samples.

Statistical Information

P-Value

0.019

Confidence Interval

95% CI 1.10-4.53

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1002/advs.202406448

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication